ArticleScientific reports2026
A perforator-based adipocutaneous skin paddle derived from free muscle flap reconstruction as a hypothesis-generating human tissue model of early localized lymphatic insufficiency.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary lymphedema remains poorly understood, particularly with regard to early human tissue responses after lymphatic outflow disruption. This study evaluates the perforator-based adipocutaneous skin paddle (PBASP) from vascularized free muscle flaps as a hypothesis-generating human tissue platform for early localized lymphatic insufficiency. The PBASP, receives arterial and venous perfusion but is not reconnected to physiological lymphatic outflow and was therefore hypothesized to develop changes consistent with early local lymphatic outflow insufficiency. Tissue samples were collected from 15 patients who underwent free muscle flap transfer, with PBASP samples obtained 7-14 days post-surgery. Histological, immunofluorescence, molecular, and protein analyses were performed to assess lymphangiogenesis, inflammation, extracellular matrix remodeling, and adipogenesis. PBASP tissue exhibited epidermal thickening, dermal expansion, subcutaneous matrix loosening, and leukocyte infiltration. Immunofluorescence showed a 3.6-fold increase in LYVE-1 + lymphatic vessel cross-sectional area. Gene expression analysis revealed upregulation of markers like VEGF-C, VEGFR3, IL-6, and MMP-9. ELISA demonstrated increased LYVE-1, IL-6, and COL1A1 protein levels. Together, PBASP tissues showed structural, lymphatic-marker, inflammatory, and early remodeling changes consistent with early localized lymphatic outflow insufficiency. Together, these findings support the PBASP-derived approach as a paired human tissue platform for studying early, localized lymphatic insufficiency and for generating mechanistic hypotheses relevant to secondary lymphedema.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.